Expertise in
22
conditions

Dr. Nelli Bejanyan

Oncology
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
22 Years of Experience
Expertise in
22
conditions
Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, 
Tampa, FL 

Overview

Nelli Bejanyan is an Oncologist practicing medicine in Tampa, Florida. She has been practicing medicine for over 22 years.

Dr. Bejanyan is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Graft Versus Host Disease (cGvHD), Bone Marrow Aspiration, and Bone Graft.

She is actively involved in clinical research, co-authoring 106 peer reviewed articles and participating in 11 clinical trials. Dr. Bejanyan is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in FL

Languages Spoken

English
Armenian
Russian

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
Sunshine Health
  • EPO
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 12 Less Insurance Carriers -

Locations

Moffitt Cancer Center, Magnolia Campus
12902 Usf Magnolia Dr, Tampa, FL 33612

Additional Areas of Focus

Dr. Bejanyan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications
Enrollment Status: Recruiting
Publish Date: July 06, 2026
Intervention Type: Drug
Phase 2 Trial of Enasidenib (AG-221) Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients With IDH2 Mutation
Phase 2 Trial of Enasidenib (AG-221) Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients With IDH2 Mutation
Enrollment Status: Suspended
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drug: Enasidenib Mesylate
Study Phase: Phase 2
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression
Enrollment Status: Completed
Publish Date: April 02, 2026
Intervention Type: Drug, Procedure
Study Drugs: Pacritinib, Sirolimus, Tacrolimus
Study Phase: Phase 1/Phase 2
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
CD8 Depleted, Non-Engrafting, HLA Mismatched Unrelated Donor Lymphocyte Infusion in Patients With MDA and Secondary AML
Enrollment Status: Completed
Publish Date: February 19, 2026
Intervention Type: Drug, Biological
Study Drug: CD8-Depleted Donor Lymphocyte Infusion
Study Phase: Phase 1/Phase 2
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning for Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: December 11, 2025
Intervention Type: Radiation, Drug
Study Drugs: Fludarabine, Melphalan
Study Phase: Phase 2
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
A Phase I/II Trial of Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms
Enrollment Status: Terminated
Publish Date: December 04, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
A Phase 2 Study of Donor-Derived Multi-Tumor-Associated Antigen Specific T Cells (MT-401) Administered to Patients With Acute Myeloid Leukemia (AML) Following Hematopoietic Stem Cell Transplantation
Enrollment Status: Terminated
Publish Date: October 30, 2025
Intervention Type: Drug
Study Drug: Zelenoleucel
Study Phase: Phase 2
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haploidentical Related Hematopoietic Cells (Haplo-HCT) For Patients With Hematologic Malignancies
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Biological, Drug
Study Drugs: Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Study Phase: Phase 2
A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome
A Phase 1/1b Safety Study of PRGN-3006 Adoptive Cellular Therapy in Patients with CD33-Positive Relapsed or Refractory Acute Myeloid Leukemia, Minimal Residual Disease Positive Acute Myeloid Leukemia, and Higher Risk Myelodysplastic Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2024
Intervention Type: Drug
Study Drug: PRGN-3006 T Cells
Study Phase: Phase 1
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
A Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haploidentical Peripheral Blood Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: September 16, 2021
Intervention Type: Drug, Procedure, Radiation
Study Phase: Phase 1
View 9 Less Clinical Trials

106 Total Publications

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.
Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis.
Journal: Blood advances
Published: April 08, 2026
Similar Doctors
Expertise in
30
conditions
Expertise in
30
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-934-6811
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Philippe Spiess is an Oncologist practicing medicine in Tampa, Florida. Dr. Spiess is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Penile Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Penectomy. Dr. Spiess is currently accepting new patients.

Expertise in
37
conditions
Expertise in
37
conditions
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
888-663-3488
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Julio Chavez is an Oncologist practicing medicine in Tampa, Florida. Dr. Chavez is highly rated in 37 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Aspiration. Dr. Chavez is currently accepting new patients.

Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Expertise in
55
conditions
Dr. Lubomir Sokol
Hematology | Oncology
Referral may be required

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr, 
Tampa, FL 
 (0.1 miles away)
813-692-4147
Languages Spoken:
English, Czech, Russian
See accepted insurances
Accepting New Patients
Offers Telehealth

Lubomir Sokol is a Hematologist and an Oncologist practicing medicine in Tampa, Florida. Dr. Sokol is highly rated in 55 conditions, according to our data. His clinical expertise encompasses T-Cell Lymphoma, Cutaneous T-Cell Lymphoma (CTCL), Non-Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Sokol is currently accepting new patients.

Frequently Asked Questions about Dr. Nelli Bejanyan

How do I make an appointment with Dr. Nelli Bejanyan?

You can book an appointment with Dr. Nelli Bejanyan by calling their office at 813-587-2469. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Nelli Bejanyan a top-rated expert for Acute Myeloid Leukemia (AML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Nelli Bejanyan is classified as an Elite expert for Acute Myeloid Leukemia (AML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Nelli Bejanyan specialize in?

While Dr. Nelli Bejanyan is a Oncology, they have specific expertise in Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Chronic Graft Versus Host Disease (cGvHD). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Nelli Bejanyan participate in research or clinical trials?

Yes. Dr. Nelli Bejanyan has published 106 articles and abstracts on conditions like Acute Myeloid Leukemia (AML). You can view a list of Dr. Nelli Bejanyan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Nelli Bejanyan accept my insurance?

Dr. Nelli Bejanyan accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 813-587-2469 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bejanyan's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile